Zobrazeno 1 - 10
of 15
pro vyhledávání: '"33"'
Autor:
YUKARI BANDO, JUNYA FURUKAWA, YASUYOSHI OKAMURA, TAKUTO HARA, TOMOAKI TERAKAWA, YUZO NAKANO, MASATO FUJISAWA
Publikováno v:
Anticancer research. 42(2)
The survival benefit of immune checkpoint inhibitors for non-clear cell renal cell carcinoma (nccRCC) is unclear. Our purpose was to evaluate the real-world survival benefit of ipilimumab plus nivolumab retrospectively.We retrospectively reviewed med
Autor:
Takayuki Shiraki, Takatsugu Matsumoto, Takamune Yamaguchi, Yukihiro Iso, Yuhki Sakuraoka, Taku Aoki, Keiichi Kubota, Shozo Mori, Takayuki Shimizu, Kyung Hwa Park
Publikováno v:
Anticancer research. 41(10)
BACKGROUND/AIM The efficacy and feasibility of gemcitabine plus cisplatin (GC) chemotherapy in an adjuvant setting is unclear in patients with biliary tract cancer (BTC) undergoing major hepatectomy. PATIENTS AND METHODS Patients with BTC who underwe
Autor:
Tomonori Hirashima, Fumio Imamura, Yoshihiko Taniguchi, Akihiro Tamiya, Kei Kunimasa, Hidekazu Suzuki, Toru Kumagai, Madoka Kimura, Motohiro Tamiya, Kenji Nakahama, Kazumi Nishino, Takako Inoue, Kazunori Moriizumi, Hanako Kuhara, Shinji Atagi
Publikováno v:
Anticancer Research. 39:3923-3929
Background/aim Treatment with EGFR-tyrosine kinase inhibitor (TKI) shows a durable response against NSCLC harboring EGFR mutation; however, treatment resistance occurs within 1-1.5 years following first-line EGFR-TKIs [first- and second-generation (G
Autor:
Giannis, Mountzios, Xanthippi, Mavropoulou, Georgia-Angeliki, Koliou, Helena, Linardou, Epaminontas, Samantas, Paris, Kosmidis, George, Fountzilas, Aphrodite, Charitandi, Anna, Kalogera-Fountzila
Publikováno v:
Anticancer research. 40(4)
The mechanism of action of bevacizumab and erlotinib is quite different in the treatment of advanced non-small cell lung cancer (NSCLC). This study sought to compare the two targeted therapies in terms of sequential tumor response metrics.Parameters
Autor:
Joji Sakurai, Ken-Ichi Arita, Souichi Kitaguchi, Isao Murakami, Kikuo Nakano, Masahiro Yamasaki, Mihoko Doi, Noboru Hattori, Tomohiro Kondo
Publikováno v:
Anticancer Research. 37:923-928
Aim We aimed to evaluate the efficacy and safety of carboplatin plus weekly paclitaxel with bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Patients and methods Patients with stage IIIB/IV or postoperative recur
Autor:
Florian Huemer, Richard Greil, Hanno Ulmer, Ewald Wöll, Lukas Weiss, Josef Thaler, Wolfgang Eisterer, Vera Trommet, Michael Hejna, Felix Keil, Birgit Gruenberger, Michael A. Fridrik
Publikováno v:
Anticancer Research. 37
Background/aim Although high response rates using the doublet-chemotherapy of oxaliplatin and irinotecan as well as its combination with cetuximab in advanced gastric cancer were shown in previous trials, time to progression was short, suggesting acq
Autor:
Ciro, Franzese, Antonella, Fogliata, Davide, Franceschini, Elena, Clerici, Giuseppe, D'Agostino, Piera, Navarria, Pietro, Mancosu, Stefano, Tomatis, Luca, Cozzi, Marta, Scorsetti
Publikováno v:
Anticancer research. 36(7)
Radiotherapy is a common approach for treating squamous cell carcinoma (SCC) of the oropharynx. We aimed to analyze toxicity and outcome of patients affected by oropharyngeal SCC treated with volumetric modulated arc therapy (VMAT).Fifty-four patient
Autor:
Shinsuke, Sasada, Makoto, Kodaira, Tatsunori, Shimoi, Akihiko, Shimomura, Mayu, Yunokawa, Kan, Yonemori, Chikako, Shimizu, Yasuhiro, Fujiwara, Kenji, Tamura
Publikováno v:
Anticancer research. 36(5)
No standard chemotherapy for adults with recurrent/refractory rhabdomyosarcoma (RMS) has yet been established. The present study aimed to assess the effect of ifosfamide and etoposide (IE) chemotherapy on previously treated RMS.Adults with recurrent/
Autor:
Satoru, Iwasa, Hiroaki, Souda, Kentaro, Yamazaki, Daisuke, Takahari, Yuji, Miyamoto, Yasumasa, Takii, Satoshi, Ikeda, Tetsuya, Hamaguchi, Yukihide, Kanemitsu, Yasuhiro, Shimada
Publikováno v:
Anticancer research. 35(3)
Preoperative chemoradiotherapy followed by total mesorectal excision (TME) is the standard treatment for stage III lower rectal cancer worldwide. However, in Japan, the standard treatment is TME with lateral pelvic lymph node dissection (LPLD) follow
A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer
Autor:
Cecilie, Holländer, Lene, Baeksgaard, Morten, Sorensen, Per, Albertsson, Lars, Damstrup, Ulrik, Lassen
Publikováno v:
Anticancer research. 32(9)
To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of concurrent chemoradiotherapy and cetuximab in patients with non-resectable locally advanced esophageal cancer.Escalating doses of oxaliplatin every second week and d